TATX 03
Alternative Names: PolyTope® TATX-03 antibody cocktail therapy; TATX-03; TATX-03 PolyTope™ Therapy; TATX-03a; TATX-03bLatest Information Update: 04 Dec 2023
At a glance
- Originator Talem Therapeutics
- Class Anti-inflammatories; Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 04 Dec 2023 TATX 03 is available for licensing as of 04 Dec 2023. https://www.talemtherapeutics.com/antibody-therapeutics-pipeline
- 15 Sep 2022 Updated pharmacodynamics data from a preclinical trial in COVID-2019 infections released by ImmunoPrecise Antibodies
- 29 Aug 2022 Updated pharmacodynamics data from a preclinical trial in COVID-2019 infections released by ImmunoPrecise Antibodies